HUMALOG KWIKPEN
Humalog is a rapid-acting human insulin analog indicated to improve glycemic control. It is used in both adult and pediatric patients diagnosed with diabetes mellitus. As an insulin analog, it serves as a therapeutic intervention to manage blood sugar levels in these patient populations.
How HUMALOG KWIKPEN Works
Humalog regulates glucose metabolism by lowering blood glucose levels through several biological pathways. It stimulates peripheral glucose uptake by skeletal muscle and fat while simultaneously inhibiting the production of glucose in the liver. Additionally, the drug inhibits the breakdown of fats and proteins and enhances protein synthesis.
Details
- Status
- Prescription
- First Approved
- 1996-06-14
- Routes
- SUBCUTANEOUS, INJECTION
- Dosage Forms
- SOLUTION, INJECTABLE
HUMALOG KWIKPEN Approval History
What HUMALOG KWIKPEN Treats
1 indicationsHUMALOG KWIKPEN is approved for 1 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Diabetes
Drugs Similar to HUMALOG KWIKPEN
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
HUMALOG KWIKPEN FDA Label Details
ProIndications & Usage
FDA Label (PDF)HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. HUMALOG is a rapid acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.